Activation of Serotonin 2C Receptors in Dopamine Neurons Inhibits Binge-like Eating in Mice by Xu, Pingwen et al.
iological
sychiatryPriority Communication BPActivation of Serotonin 2C Receptors in
Dopamine Neurons Inhibits Binge-like
Eating in Mice
Pingwen Xu, Yanlin He, Xuehong Cao, Lourdes Valencia-Torres, Xiaofeng Yan,
Kenji Saito, Chunmei Wang, Yongjie Yang, Antentor Hinton Jr., Liangru Zhu,
Gang Shu, Martin G. Myers Jr., Qi Wu, Qingchun Tong, Lora K. Heisler, and Yong XuABSTRACT
BACKGROUND: Neural networks that regulate binge eating remain to be identiﬁed, and effective treatments for
binge eating are limited.
METHODS: We combined neuroanatomic, pharmacologic, electrophysiological, Cre-lox, and chemogenetic
approaches to investigate the functions of 5-hydroxytryptamine (5-HT) 2C receptor (5-HT2CR) expressed by
dopamine (DA) neurons in the regulation of binge-like eating behavior in mice.
RESULTS: We showed that 5-HT stimulates DA neural activity through a 5-HT2CR-mediated mechanism, and
activation of this midbrain 5-HT→DA neural circuit effectively inhibits binge-like eating behavior in mice. Notably,
5-HT medications, including ﬂuoxetine, d-fenﬂuramine, and lorcaserin (a selective 5-HT2CR agonist), act on
5-HT2CRs expressed by DA neurons to inhibit binge-like eating in mice.
CONCLUSIONS: We identiﬁed the 5-HT2CR population in DA neurons as one potential target for antibinge therapies,
and provided preclinical evidence that 5-HT2CR agonists could be used to treat binge eating.
Keywords: Binge eating, Dopamine, Lorcaserin, Neuron, Receptor, SerotoninISShttp://dx.doi.org/10.1016/j.biopsych.2016.06.005Binge eating, deﬁned as the ingestion of a large amount of
food in short timeframe, is a central feature of eating disorders
such as bulimia nervosa and binge eating disorder (1,2)
and is prevalent in approximately 5% of U.S. adults (3). The
pathophysiology of binge eating in humans is not well under-
stood, and the effective treatments for this condition are
limited.
Impaired brain 5-hydroxytryptamine (5-HT; serotonin) sig-
naling is linked to the development of binge eating in humans
(4–7). For example, binge eating patients are found to have
increased brain 5-HT uptake and consequently decreased
5-HT content (4). In addition, effects of 5-HT precursor
L-tryptophan are signiﬁcantly blunted in binge eating patients,
presumably due to dysfunctions of 5-HT receptors and/or
tryptophan hydroxylase-2 (TPH2) (4), the enzyme that synthe-
sizes 5-HT in the brain. Furthermore, selective serotonin
reuptake inhibitors that increase central 5-HT content, such
as ﬂuoxetine, suppress binge eating (8–13). Notably, d-
fenﬂuramine (d-Fen), a drug that increases 5-HT content (14),
effectively reduces the number of binge episodes in severely
obese patients (15,16). However, d-Fen was withdrawn from
clinical use because of adverse cardiopulmonary events (17).
Due to the effect of these 5-HT compounds on binge eating,
efforts have been focused on understanding the mechanisms
underlying their antibinge beneﬁts, with an attempt to facilitate& 2016 Society of B
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SEE CORRESPONDING ARthe development of new pharmaceutical agents that suppress
binge eating, with fewer side effects.
The central dopamine (DA) system is also implicated in the
pathophysiology of binge eating (18). For instance, human
genetic studies have shown an increased frequency of DA
transporter (DAT) and D2 receptor polymorphisms with binge
pathology (19). Rats that binge sucrose demonstrate
increased DA release in the nucleus accumbens (20,21), a
ventral striatal structure that receives dopaminergic projec-
tions from the ventral tegmental area (VTA) (22,23). Interest-
ingly, deep brain stimulation targeting the shell of nucleus
accumbens potently inhibits binge eating in mice (24). Fur-
thermore, raclopride, a nonselective D2 receptor antagonist
that presumably activates DA neurons (25), suppresses binge
eating in rats (26,27). Together, these suggest a potential role
of DA neurons in the pathophysiology and treatment of binge
eating. Interestingly, 5-HT neurons in the dorsal raphe nuclei
(DRN) directly project to and synapse on DA neurons in the
VTA (28), which provides an anatomic framework for an
interaction between 5-HT and DA that may have relevance
to the regulation of binge eating.
An intermittent high-fat diet (HFD) exposure paradigm has
been used by others and us to induce binge-like eating
behavior in mice and rats that in many ways simulates binge
eating in humans (24,29–31). In the current study, we used thisiological Psychiatry. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Psychiatrybinge-inducing paradigm to ﬁrst conﬁrm antibinge efﬁcacy of
ﬂuoxetine and d-Fen in wild-type (WT) mice. We then com-
bined a variety of genetic mouse models to determine whether
serotonin 2C receptors (5-HT2CRs) expressed in DA neurons
are required or sufﬁcient to mediate inhibitory effects of these
5-HT drugs on binge-like eating behavior. Furthermore, we
assessed whether a Food and Drug Administration–approved
5-HT2CR agonist (lorcaserin) acts on this 5-HT2CR population
to inhibit binge-like eating behavior in mice. Finally, electro-
physiological recordings and designer receptors exclusively
activated by designer drugs (DREADD) approaches were used
to determine whether 5-HT drugs inhibit binge-like eating via
regulating DA neural activity.METHODS AND MATERIALS
Mice
All the transgenetic breeders have been backcrossed to
C57BL/6 background for more than 12 generations (see
Supplement for detailed breeding strategies). Mice were
housed in a temperature-controlled environment in groups of
two to ﬁve at 221C to 241C using a 12-hour light/dark cycle.
The mice were fed standard chow (6.5% fat, #2920, Harlan-
Teklad, Madison, WI) until training and assessment of binge-
like eating behavior. Water was provided ad libitum.
Effects of 5-HT Compounds on Binge-like Eating
Behavior
Mice (12 weeks of age) were subjected to either “intermittent”
HFD exposure or “continuous” chow/HFD exposure, as
described in the Supplement. On the binge assessment days,
mice received intraperitoneal (i.p.) injections of saline, or
various 5-HT compounds, at 10:30 AM (30 minutes before
assessment). The same mice received all different injections in
different cycles. The order of injections was randomized to
avoid potential sequence effects.
DREADD-Induced Activation of DA Neurons and
Binge-like Eating Behavior
DAT-CreER mice (male and female, 12 weeks of age) were
anesthetized with isoﬂurane and received stereotaxic injec-
tions of the excitatory adeno-associated virus (AAV)-hM3Dq-
mCherry DREADD virus (200 nL/site; University of North
Carolina Gene Therapy Center, Chapel Hill, NC) into both sites
of VTA or into both sites of the substantia nigra (SN). These
mice also received i.p. injections of tamoxifen (4 mg/mouse).
After a 7-day recovery, mice were subjected to the intermittent
HFD exposure to induce binge-like eating, as we have
described. On the binge assessment days, mice received i.p.
injections of saline or clozapine N-oxide ([CNO]; 1 mg/kg #HY-
17366; MedChem Express, Monmouth Junction, NJ), at 10:30
AM (30 minutes before assessment). To assess binge-like
eating, 2.5-hour HFD intake was measured. The same mice
received both saline and CNO injections in different cycles.
The order of injections was randomized to avoid potential
sequence effects.738 Biological Psychiatry May 1, 2017; 81:737–747 www.sobp.org/jouStatistics
The minimum sample size was predetermined by the nature of
experiments. For most of the physiological readouts (e.g., food
intake), at least six mice per group were included. For
histology studies, two or three mice were included in each
group. For electrophysiological studies, at least 17 neurons in
each genotype or condition were included. The data are
presented as mean 6 SEM. Statistical analyses were per-
formed using GraphPad Prism (GraphPad Software, San
Diego, CA) to evaluate normal distribution and variations within
and among groups. Methods of statistical analyses were
chosen based on the design of each experiment and are
indicated in ﬁgure legends. p , .05 was considered to be
statistically signiﬁcant.
See Supplement for detailed methods.
RESULTS
5-HT2CRs Largely Mediate Effects of Fluoxetine and
d-Fen to Inhibit Binge-like Eating in Mice
We used an established protocol (29), intermittent HFD
exposure, to train mice to develop binge-like eating behavior
(Figure 1A). After an initial 1-week training, these intermittent
mice developed a repetitive eating behavior that mimics many
characteristics of binge eating in humans. For example,
intermittent mice ate a large amount of HFD over a short
period of time (between 11:00 AM and 1:30 PM) (Figure 1B). A
preference for high palatability was clearly observed in these
mice, with about 0.8 g HFD intake compared with minimal
chow intake during this 2.5-hour period (Figure 1B). In con-
trast, control mice, those exposed either to continuous chow/
HFD feeding or to continuous chow feeding, ate minimal
amounts HFD and/or chow during the same period
(Figure 1B). We conﬁrmed that these intermittent mice were
satiated during this binging period, because when these mice
were provided only chow, instead of chow and HFD, they ate
minimal food, which was comparable to that of control mice
(Figure 1C). Finally, the binge-like eating seen in intermittent
mice was repetitive and persisted for at least seven cycles
without any evidence of habituation (Figure 1D), which is
similar to the recurrent binge episodes in patients. Thus, we
measured the 2.5-hour HFD intake in intermittent mice to
assess binge-like eating behavior in the following studies.
We ﬁrst showed that i.p. injections of ﬂuoxetine (10 mg/kg)
or d-Fen (3 mg/kg) signiﬁcantly suppressed binge-like eating
in WT mice (Figure 1E). However, in a loxed transcription
blocker (loxTB) 5-HT2CR (2C-null) mouse line lacking func-
tional 5-HT2CRs globally (32,33), neither ﬂuoxetine nor d-Fen
inhibited binge-like eating (Figure 1E). These results indicate
that the inhibitory effects of these 5-HT drugs on binge-like
eating are mediated in part through the 5-HT2CR, one of the
14 known receptors for 5-HT in mammals. As a non-binge-
eating control group, another cohort of WT and 2C-null mice
were subjected to the continuous chow/HFD exposure. The
2.5-hour HFD intake in these “continuous” mice was minimal,
and importantly, no signiﬁcant effects of ﬂuoxetine and d-Fen
were observed during this period in either WT or 2C-null mice
(Figure 1F).rnal
5-HT2CR Activates DA to Modulate Binge Eating
Biological
Psychiatry5-HT Neurons Innervate DA Neurons
VTA DA neurons (DAVTA) coexpress 5-HT2CRs (34). Given that
dysfunctions of brain DA system are implicated in the develop-
ment of binge eating in humans (18,19), we speculated that
5-HT2CRs expressed by DA neurons may be involved in the
inhibitory effects of 5-HT drugs on binge-like eating. To test
this possibility, we ﬁrst used TPH2-CreER mice that express
tamoxifen-inducible Cre recombinase exclusively in TPH2-
expressing neurons. We crossed TPH2-CreER mice with
Rosa26-tdTOMATO mice to generate TPH2-CreER/Rosa26-
tdTOMATO mice. After tamoxifen inductions (4 mg/mouse,
i.p.) in these mice, we detected abundant TOMATO-labeled
cell bodies in the DRN, median raphe nuclei (MRN), and caudal
raphe nuclei (Figure 2A–C). We further observed intensive
TOMATO-positive terminals in the VTA, with fewer terminals
in the adjacent SN (Figure 2D, E). These results suggest that
5-HT neurons project to the VTA as well as SN. To directly
determine which subsets of 5-HT neurons project to the VTA/
SN, we stereotaxically injected Cre-dependent AAV express-
ing channelrhodopsin-2 (ChR2) enhanced yellow ﬂuorescent
protein (EYFP) into the DRN of TPH2-CreER mice to effec-
tively infect 5-HTDRN neurons (Figure 2F–I), and observed
ChR2-EYFP–labeled ﬁbers in the VTA and SN, which were in
close proximity with tyrosine hydroxylase-positive neurons
(Figure 2J–Q). When this AAV virus was injected in the MRNFigure 1. 5-Hydroxytryptamine drugs inhibit binge-like eating via 5-hydroxytr
binge and control mice. In the ﬁrst week, binge mice were exposed to both a regu
Wednesday 11:00 AM), and then exposed to only chow for the rest of the week. O
cages at 11:00 AM and removed at 11:00 AM on Tuesday. The same cycles were
provided with chow and HFD all the time (continuous chow/HFD feeding), and a
2.5-hour diet intake in intermittent mice and two control groups from 11:00 AM to
mean 6 SEM. ***p , .001 in two-way analyses of variance followed by post hoc
continuous chow mice from 11:00 AM to 1:30 PM on binge day (red B) when only
SEM. (D) We measured 2.5-hour HFD intake on the binge day of seven repeated
feeding. n 5 6 or 7 per group. Results are shown as mean 6 SEM. *p , .05 b
analyses of variance followed by post hoc Sidak tests. (E) Effects of intraperitone
kg) on binge-like eating (2.5-hour HFD intake) in wild-type (WT) or 2C-null mice ex
as mean 6 SEM. *p , .05 and **p , .01 between drug treatment and saline treatm
hoc Sidak tests. (F) Effects of intraperitoneal injections of saline, ﬂuoxetine (10
exposed to continuous chow/HFD feeding. n 5 6 or 7 per group. Results are sh
Biologicaof TPH2-CreER mice (Figure 2R), only scarce ChR2-EYFP–
labeled ﬁbers were observed in the VTA/SN (Figure 2S, T).
These results indicate that the VTA/SN receive projections
from 5-HTDRN neurons and, to a lesser extent, from 5-HTMRN
neurons.
We then stereotaxically injected Ad-IN/W (35) into the DRN
of TPH2-CreER mice. On tamoxifen induction, these mice
expressed green ﬂuorescent protein–tagged wheat germ
agglutinin ([WGA], which is an anterograde trans-synaptic
tracer) speciﬁcally in 5-HTDRN neurons (Figure 2U). As
expected, WGA immunoreactivity was observed in brain
regions that are innervated by 5-HT neurons (36), including
the red nucleus, the arcuate nucleus, and the paraventricular
nucleus of the hypothalamus (Supplemental Figure S1A–F).
Importantly, we also detected WGA-labeled neurons in the
VTA, the majority of which were conﬁrmed to be DA neurons
with costaining of tyrosine hydroxylase (Figure 2V–X). Collec-
tively, these data established a neural circuit in which 5-HTDRN
neurons innervate DAVTA neurons.
5-HT2CR in DA Neurons Mediates Effects of
Fluoxetine and d-Fen on Binge-like Eating in Mice
We crossed DAT-CreER mice with Rosa26-tdTOMATO mice
to generate DAT-CreER/Rosa26-tdTOMATO mice and con-
ﬁrmed that Cre-induced TOMATO expression was exclusivelyyptamine 2C receptor–mediated mechanisms. (A) Study paradigm to train
lar chow (C) and high-fat diet (HFD [H]) for 2 days (from Monday 11:00 AM to
n the binge day (red B, Monday of the second week), HFD was returned to
repeated as the second week. As control subjects, one group of mice was
nother group was fed with chow (continuous chow only). (B) We measured
1:30 PM on binge day (red B). n 5 7 or 10 per group. Results are shown as
Sidak tests. (C) We measured 2.5-hour chow intake in intermittent mice and
chow was provided. n 5 12 or 14 per group. Results are shown as mean 6
cycles in mice exposed to either continuous chow/HFD or intermittent HFD
etween continuous and intermittent groups at the same cycle in two-way
al injections of saline, ﬂuoxetine (10 mg/kg), or d-fenﬂuramine (d-Fen) (3 mg/
posed to intermittent HFD feeding. n 5 6 to 10 per group. Results are shown
ent in the same genotype in two-way analyses of variance followed by post
mg/kg), or d-Fen (3 mg/kg) on 2.5-hour HFD intake in WT or 2C-null mice
own as mean 6 SEM. ns, not signiﬁcant.
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Figure 2. 5-Hydroxytryptamine (5-HT) neurons synapse on
dopamine neurons. (A–E) TOMATO-labeled cell bodies (A–C)
and TOMATO-positive ﬁbers (D, E) in the brain of tryptophan
hydroxylase-2 (TPH2)-CreER/Rosa26-tdTOMATO mice (after
tamoxifen induction). (E) Higher magniﬁcation of the white box
in (D). (F–Q) AAV-EF1α-DIO hChR2(H134R)-EYFP was injected
into the dorsal raphe nuclei (DRN) of TPH2-CreER mice (with
tamoxifen induction). (F) A low-magniﬁcation image for the
injection site showing enhanced yellow ﬂuorescent protein
(EYFP)-labeled cell bodies and ﬁbers within the DRN; (G–I)
High-magniﬁcation images of the white box in (F), showing
EYFP exclusively colocalized with 5-HT (arrow-pointed neu-
rons). (J–M) The projections in the ventral tegmental area (VTA)
are indicated, showing EYFP-labeled ﬁbers in the close
proximity with tyrosine hydroxylase (TH)-labeled cell bodies.
(N–Q) The fewer projections in the substantia nigra (SN) are
indicated. (R–T) AAV-EF1α-DIO hChR2(H134R)-EYFP was
injected into the median raphe nuclei (MRN) of TPH2-CreER
mice (with tamoxifen induction). (R) The injection site is
indicated, showing EYFP-labeled cell bodies and ﬁbers within
the MRN; (S, T) indicate scarce EYFP-labeled ﬁbers in the
ventral tegmental area (VTA) and SN. (U–X) Ad-IN/W virus was
injected into the DRN of TPH2-CreER mice (with tamoxifen
induction). (U) The injection site is indicated, showing wheat
germ agglutinin (WGA)-labeled neurons within the DRN; (V–X)
indicate anterograde WGA signals in the VTA, largely coloca-
lized with TH. Scale bars are indicated in each image. Scale
bars = 500 μm in (A-D), 100 μm in (E, F, J–L, N–P, R–T, U),
50 μm in (V–X), 25 μm in (G–I), and 6.25 μm in (M, Q). Arrows in
(N–P) point to double-labeled neurons. 4V, fourth ventricle;
AAV, adeno-associated virus; Aq, aqueduct; ChR2, channelr-
hodopsin-2; CRN, caudal raphe nuclei; IP, interpeduncular
nucleus; xscp, decussation of superior cerebellar peduncle.
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Psychiatrylocated in DA neurons in the VTA and SN (Supplemental
Figure S2A–C), but not in other brain regions (Supplemental
Figure S2D–F). Importantly, DAT-CreER/Rosa26-tdTOMATO
mice without tamoxifen induction do not show any leaking Cre
activity (Supplemental Figure S2G).740 Biological Psychiatry May 1, 2017; 81:737–747 www.sobp.org/jouWe then crossed DAT-CreER mice to 2C-null (loxTB-5-
HT2CR) mice to generate littermates of WT mice, 2C-null mice,
and DA-2C-RE mice (those carrying both mutations). In DA-
2C-RE mice, tamoxifen-induced Cre recombinase is expected
to remove the loxTB cassette and reactivate expression ofrnal
Figure 3. 5-Hydroxytryptamine 2C
receptors (5-HT2CRs) in dopamine
(DA) neurons mediate effects of 5-HT
drugs to inhibit binge-like eating. (A)
Illustration of 5-HT2CR expression pat-
tern in wild-type (WT), 2C-null, DA-2C-
RE or DA-2C-KO mice. Blue indicates
the distribution of 5-HT2CRs (note that
5-HT2CRs are reported to be exclu-
sively in the brain); the red box indi-
cates DA neural population. (B) Effects
of intraperitoneal (i.p.) injections of sal-
ine, ﬂuoxetine (10 mg/kg), or d-fenﬂur-
amine (d-Fen) (3 mg/kg) on binge-like
eating (2.5-hour high-fat diet [HFD]
intake) in four groups of mice that all
received tamoxifen and were exposed
to intermittent HFD feeding. n 5 6 to 9
per group. Results are shown as mean
6 SEM. *p , .05 between drug treat-
ment and saline treatment in the same
genotype in two-way analyses of var-
iance (ANOVAs) followed by post hoc
Sidak tests. (C) Effects of i.p. injections
of saline, lorcaserin (3 mg/kg), or lorca-
serin (6 mg/kg) on 2.5-hour HFD intake
in WT mice exposed to intermittent
HFD feeding or continuous chow/HFD
feeding. n 5 10 to 12 per group.
Results are shown as mean 6 SEM.
*p , .05 between drug treatment and
saline treatment in the same feeding
paradigm in two-way ANOVAs followed by post hoc Sidak tests. (D) Effects of i.p. injections of saline or lorcaserin (6 mg/kg) on binge-like eating (2.5-hour HFD
intake) in four groups of mice that all received tamoxifen and were exposed to intermittent HFD feeding. n 5 7 to 10 per group. Results are shown as mean 6
SEM. *p , .05 and **p , .01 between lorcaserin treatment and saline treatment in the same genotype in two-way ANOVAs followed by post hoc Sidak tests. (E)
Effects of i.p. injections of saline or lorcaserin (6 mg/kg) on 2-hour refeeding after an overnight fast in four groups of mice that all received tamoxifen and were
maintained on chow diet. n 5 7 to 15 per group. Results are shown as mean 6 SEM. *p , .05 between lorcaserin treatment and saline treatment in the same
genotype in two-way ANOVAs followed by post hoc Sidak tests. KO, knockout; ns, not signiﬁcant; RE, re-expression.
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(Figure 3A), WT mice express 5-HT2CR messenger RNAs
(detected by reverse transcriptase polymerase chain reaction)
in all brain regions examined, including the amygdala, frontal
cortex, hypothalamus, and VTA, whereas 2C-null mice do not
express 5-HT2CR messenger RNAs in any of these regions
(Supplemental Figure S2H). DA-2C-RE mice express 5-HT2CR
messenger RNAs in the VTA, but not in other brain regions
(Supplemental Figure S2H).
We showed that both ﬂuoxetine and d-Fen signiﬁcantly
suppressed binge-like eating in WT mice, but these effects
were blunted in 2C-null mice (Figure 3B). Importantly, we
showed that the antibinge effects of ﬂuoxetine and d-Fen were
largely restored in DA-2C-RE mice (Figure 3B). These data
indicate that 5-HT2CRs expressed by DA neurons alone are
sufﬁcient to restore antibinge effects of 5-HT drugs in mice.
We have recently generated a lox-5-HT2CR mouse, in which
the critical coding region of the 5-HT2CR gene was ﬂanked by
two loxP sites and can be deleted in Cre-positive cells (37).
Here we crossed DAT-CreER mice with lox-5-HT2CR mice to
generate DA-2C-KO mice (those carrying both mutations). In
DA-2C-KO mice, tamoxifen-induced Cre recombinase resulted
in deletion of endogenous 5-HT2CRs only in DA neurons (as
illustrated in Figure 3A). Interestingly, we found that both
ﬂuoxetine and d-Fen failed to impact binge-like eating in DA-
2C-KO mice (Figure 3B). These data indicate that 5-HT2CRsBiologicaexpressed by DA neurons are required to mediate antibinge
effects of 5-HT medications.Lorcaserin Acts on 5-HT2CRs in DA Neurons to
Inhibit Binge-like Eating in Mice
A selective 5-HT2CR agonist, lorcaserin (Arena Pharmaceut-
icals, San Diego, CA), was approved by the Food and Drug
Administration for obesity treatment in 2012 and has been
prescribed to obese patients at 10 mg (twice a day). Here we
showed that lorcaserin at 6 mg/kg, but not at 3 mg/kg,
signiﬁcantly inhibited binge-like eating (Figure 3C). These
results indicate that lorcaserin is effective in suppressing
binge-like eating behavior in mice. We further tested antibinge
effects of lorcaserin (6 mg/kg) in WT, 2C-null, DA-2C-RE, and
DA-2C-KO mice (all of which ﬁrst received tamoxifen injections
and were then subjected to the intermittent HFD exposure).
Similar to ﬂuoxetine and d-Fen, lorcaserin signiﬁcantly sup-
pressed HFD intake in WT mice, but these effects were
attenuated in both in 2C-null mice and in DA-2C-KO mice
(Figure 3D). Importantly, re-expression of 5-HT2CRs only in DA
neurons in DA-2C-RE mice was sufﬁcient to restore antibinge
effects of lorcaserin close to the level observed in WT mice
(Figure 3D). Together, these results highlight the 5-HT2CR in
DA neurons as a key mediator for the inhibitory effects of
lorcaserin on binge-like eating in mice.l Psychiatry May 1, 2017; 81:737–747 www.sobp.org/journal 741
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Lorcaserin on Hunger-Driven Food Intake in Mice
Agonists of the 5-HT2CR, including lorcaserin (3–24 mg/kg),
strongly suppress fast-induced refeeding in animals (38),
indicating that 5-HT2CR signals also regulate feeding behavior
driven by hunger. To further determine whether 5-HT2CRs in
DA neurons are also involved in hunger-driven feeding, we
tested effects of lorcaserin on fast-induced refeeding in
another cohort of mice. We found that lorcaserin (6 mg/kg,
i.p.) signiﬁcantly inhibited 2-hour food intake in WT mice that
had fasted overnight (Figure 4E). The lorcaserin-induced
anorexia was blocked in 2C-null (Figure 3E), conﬁrming that
effects of lorcaserin on hunger-driven feeding are mediated
through 5-HT2CRs. Importantly, re-expression of 5-HT2CRs in
DA neurons (in DA-2C-RE mice) failed to rescue the lorcaserin-
induced anorexia (Figure 4E). In addition, similarly as for WT
mice, DA-2C-KO mice with 5-HT2CRs selectively deleted in DA
neurons responded to lorcaserin with signiﬁcantly decreased
food intake (Figure 3E). Similar patterns were observed at
4 and 6 hours after refeeding (Supplemental Figure S4).
Together, our results indicate that 5-HT2CRs mediate lorca-
serin actions to suppress hunger-driven feeding behavior, but
these effects are not dependent on 5-HT2CRs expressed by
DA neurons.
Lorcaserin Activates DA Neurons via 5-HT2CR–
Mediated Mechanisms
To delineate the cellular mechanisms by which 5-HT2CRs
inﬂuence DA neuron activity, we visualized DA neurons
(Figure 4A–F) with and without altered 5-HT2CR expression
through intercrossing mice with a Rosa26-tdTOMATO allele
with DAT-CreER, DA-2C-RE, and DA-2C-KO mice, respec-
tively. We ﬁrst assessed the basic electrophysiological proper-
ties of identiﬁed DAVTA neurons from WT, DA-2C-KO, and DA-
2C-RE mice. We found that the input resistances of DA
neurons from DA-2C-RE mice were signiﬁcantly lower than
DA neurons from WT mice, whereas there was no difference
between WT and DA-2C-KOmice (Supplemental Figure S10D, E).
Resting membrane potential was comparable among all geno-
types (Supplemental Figure S10F); similar proportions of DA
neurons from all genotypes ﬁred spontaneously (Supplemental
Figure S10G), and baseline ﬁring rate neurons were comparable
among the 3 genotypes (Supplemental Figure S10H).
Then we examined effects of lorcaserin on these DA neurons
from 3 genotypes. In WT mice, a portion of DA neurons (57.8%,
26 of 45) responded to lorcaserin treatment (30 mM, bath
perfusion) with depolarization (see Figure 5G for representative
traces); one DA neuron from WT mice (2.22%) was hyper-
polarized by 2.53 mV; the rest of DA neurons (40.0%, 18 of 45)
were irresponsive (#2 mV changes in resting membrane poten-
tial) (Table 1). We also showed that lorcaserin depolarized 77.8%
(14 of 18) DA neurons (see Figure 4H for representative traces) in
the presence of tetrodotoxin and a cocktail of fast synaptic
inhibitors (bicuculline, AP5 [DL-2-amino-5-phosphonovaleric
acid; Sigma-Aldrich, St. Louis, MO], and CNQX [6-cyano-7-
nitroquinoxaline-2,3-dione; Sigma-Aldrich]), indicating that this
lorcaserin-induced depolarization was mediated through a direct
action of lorcaserin on these DA neurons. Supporting this
possibility, we showed that the majority of DA neurons from742 Biological Psychiatry May 1, 2017; 81:737–747 www.sobp.org/jouDA-2C-KO mice (94.44%, 17 of 18) were irresponsive to
lorcaserin (Figure 4I and Table 1). Importantly, in DA-2C-RE
mice with 5-HT2CRs re-expressed only in DA neurons, we
found that lorcaserin depolarized 66.67% (16 of 24) DA
neurons (see Figure 4J for representative traces). We further
compared the magnitude of depolarization in various groups
and found that effects of lorcaserin in WT neurons were
signiﬁcantly diminished in DA-2C-KO neurons, but this
lorcaserin-induced depolarization was rescued in DA-2C-
RE neurons (Figure 4K). Interestingly, the depolarization in
DA-2C-RE neurons was signiﬁcantly stronger than that in WT
neurons (Figure 4K). Lorcaserin increased the ﬁring rate in
WT neurons, an effect that was blocked in DA-2C-KO
neurons, but restored in DA-2C-RE neurons (Figure 4L).
Together, these results indicate that lorcaserin activates
DAVTA neurons via 5-HT2CR-mediated mechanisms.
5-HT Inhibits Binge-like Eating by Activating DA
Neurons
DAT-CreER mice (12 weeks) received stereotaxic injections of
the excitatory DREADD virus (designer receptor, AAV-hM3Dq-
mCherry) into both sites of VTA. Upon tamoxifen injection
(4 mg, i.p.), hM3Dq-mCherry was exclusively expressed in
DAVTA neurons, as conﬁrmed by post hoc immunostaining for
mCherry (Figure 5A). Designer drug CNO administration
(1 mg/kg, i.p.) selectively activates DA neurons, as demon-
strated by induction of c-fos immunoreactivity in the VTA in
post hoc analyses (Figure 5B). As a negative control, we
conﬁrmed that saline administration did not induce c-fos
immunoreactivity in the VTA (Figure 5C). CNO adminis-
tration signiﬁcantly inhibited binge-like eating when com-
pared with saline administration (Figure 5D). As a further control
of the speciﬁcity of function of DAVTA neurons, the SN was
targeted in another group of mice (see Supplemental
Figure S11 for validation). Unlike activation of DAVTA neurons,
discrete activation of DASN neurons did not affect binge-like
eating (Figure 5D).
Next, a group of DAT-CreER mice (8 weeks) received stereo-
taxic injections of the inhibitory DREADD virus AAV-hM4Di-
mCherry into the VTA followed by treatment with tamoxifen.
Electrophysiological recordings revealed that CNO treatment (5
mM) rapidly and robustly inhibited mCherry-labeled DAVTA
neurons (Figure 5E–H). Another group of DAT-CreER mice
(12 weeks) received stereotaxic bilateral injections of AAV-
hM4Di-mCherry into the VTA. These mice then received pretreat-
ment with saline or CNO (3 mg/kg, 60 minutes before), followed
by treatment with saline or d-Fen (3 mg/kg, 30 minutes before),
and binge-like eating was measured 30 minutes later. Although
d-Fen signiﬁcantly inhibited binge-like eating in mice pretreated
with saline, in mice pretreated with CNO (DAVTA neurons
inhibited), d-Fen failed to suppress binge-like eating (Figure 5I).
These results further support that 5-HT compounds inhibit binge-
like eating through stimulating DAVTA neural activities.DISCUSSION
In the current study, we provide evidence to support that a
5-HT→DA neural circuit exerts inhibitory effects on binge-like
eating behavior in mice. We used ChR2 and WGA anterogradernal
Figure 4. Lorcaserin activates dopamine ventral
tegmental area (DAVTA) neurons via 5-hydroxytrypta-
mine 2C receptor–mediated mechanisms. (A–C)
Brightﬁeld (A), ﬂuorescent with ﬂuorescein isothiocya-
nate ﬁlter (B), and with tetramethylrhodamine ﬁlter (C)
illuminations of a targeted DAVTA neuron. Panel (B)
shows the lucifer yellow dye injected into the recorded
neuron; (C) shows TOMATO signal. Scale bars 5 10
mm. (D–F) Post hoc identiﬁcation of the recorded
neuron within the VTA in the ﬁxed brain slice. Panel
(D) shows TOMATO-labeled DA neurons in the VTA;
(E) shows the recorded neurons ﬁlled with the lucifer
yellow dye; and (F) shows the merge of (D) and (E).
Scale bars 5100 mm. (G, H) Representative traces
before and after lorcaserin treatment (30 mM, bath
perfusion) in DAVTA neurons from wild-type (WT) mice
in the absence of (G) or the presence of 1 μM
tetrodotoxin (TTX), 30 μM CNQX, 30 μM AP5, and 50
μM bicuculline (H). (I, J) Representative traces before
and after lorcaserin treatment (30 mM, bath perfusion)
in DAVTA neurons from DA-2C-KO mice (I) and DA-2C-
RE mice (J). The upper panels show the long ﬁring
traces; the lower panels show zoom-in traces before
and after lorcaserin treatment. The pie graphs in (G–J)
represent the number (percentage) of neurons with
depolarization, hyperpolarization, or no response. (K)
Magnitude of depolarization induced by lorcaserin in
various groups. n 5 18 to 45 per group. Results are
shown as mean 6 SEM. *p , .05 and **p , .01 by
unpaired t tests. (M) Changes in ﬁring rate induced by
lorcaserin in various groups. n 5 13 to 15 per group.
Results are shown as mean 6 SEM. *p , .05 by
unpaired t tests. IP, interpeduncular nucleus; KO,
knockout; RE, re-expression.
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Psychiatrytracing approaches to provide complementary evidence that
5-HT neurons primarily originating from the DRN project to
DAVTA neurons. Consistent with earlier electron microscopic
observations in rat brains (39,40) and a recent retrograde
tracing study in mice (28), our results provided neuroanatomicBiologicaevidence for the presence of a midbrain 5-HT→DA neural
circuit.
Previous observations regarding effects of 5-HT on DA
neural activity have been controversial. On one hand, micro-
infusion of 5-HT directly into the VTA of rats enhances DAl Psychiatry May 1, 2017; 81:737–747 www.sobp.org/journal 743
Figure 5. 5-Hydroxytryptamine drugs inhibit binge-like eating via stimulating dopamine ventral tegmental area (DAVTA) neurons. (A–C) Validation of AAV-
hM3Dq-mCherry-mediated activation of DA neurons in the VTA. (A) mCherry immunoreactivity after injections of excitatory AAV-hM3Dq-mCherry into the VTA
of DAT-CreER mice. (B, C) c-fos immunoreactivity in the VTA 90 minutes after injections of 1 mg/kg clozapine N-oxide (CNO) (B) or saline (C). Scale bars 5
500 μm (A) and 100 μm (B, C). (D) Effects of saline or CNO (1 mg/kg, i.p.) on binge-like eating in DAT-CreER mice receiving excitatory AAV-hM3Dq-mCherry
infection in the VTA or in the substantia nigra (SN). Results are shown as mean 6 SEM. *p , .05 by unpaired t tests. (E) Fluorescence of mCherry and lucifer
yellow, and brightﬁeld illuminations of a targeted DAVTA neuron infected with inhibitory AAV-hM4Di-mCherry. Scale bars 5 10 mm. (F) Representative
electrophysiological response to CNO (5 mM, bath) in DAVTA neurons infected with inhibitory AAV-hM4Di-mCherry. (G, H) Summary changes in resting
membrane potential (G) and in ﬁring rate (H) in DAVTA neurons infected with inhibitory AAV-hM4Di-mCherry. n 5 6/group. ***p , .001 by paired t tests. (I)
Effects of saline/CNO (3 mg/kg, i.p.) followed by saline or d-fenﬂuramine (d-Fen) (3 mg/kg, i.p.) on binge-like eating measured in DAT-CreER mice receiving
inhibitory AAV-hM4Di-mCherry infection in the VTA. n 5 6 or 7 per group. Results are shown as mean 6 SEM. *p , .05 in two-way analyses of variance
followed by post hoc Sidak tests. AAV, adeno-associated virus; DAT, dopamine transporter; DREADD, designer receptors exclusively activated by designer
drugs; HFD, high-fat diet; IP, interpeduncular nucleus; i.p., intraperitoneal.
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Psychiatryrelease (41), suggesting an excitatory effect of 5-HT on DA
neural activity. On the other hand, it was reported that the
ﬁring rate of putative DAVTA neurons in rats can be inhibited by
intravenous administration of a 5-HT2CR agonist (RO600175)
(42,43). This discrepancy may result from nonspeciﬁcity of
5-HT compounds, different delivery routes, and perhaps
unidentiﬁed neural populations in these studies. Here we used
slice electrophysiology to directly record effects of the selec-
tive 5-HT2CR agonist (lorcaserin) on neural activities of iden-
tiﬁed DAVTA neurons. Lorcaserin depolarized a large portion of
DAVTA neurons and increased their ﬁring rate. The lorcaserin-
induced depolarization persisted in the presences of tetrodo-
toxin and glutamate/gamma-aminobutyric acid receptor
antagonists, conﬁrming a direct effect of lorcaserin on DAVTA744 Biological Psychiatry May 1, 2017; 81:737–747 www.sobp.org/jouneurons. More importantly, lorcaserin-induced activation was
almost abolished in mice lacking 5-HT2CRs only in DA
neurons, but was rescued in mice with 5-HT2CRs re-
expressed only in DA neurons. Together, these studies sup-
port that 5-HT activates at least a portion of DAVTA neurons
through 5-HT2CR-mediated mechanisms. Notably, DA neurons
from DA-2C-RE mice are even more responsive to lorcaserin
treatment than those from WT mice, suggesting that in WT
mice, lorcaserin may also exert an inhibitory tone on DA
neurons via indirect mechanisms. Supporting this possibility,
DAVTA neurons are known to receive tonic inhibitory inputs
from gamma-aminobutyric acidergic interneurons (44) and
gamma-aminobutyric acidergic neurons express 5-HT2CRs
(34).rnal
Table 1. Number of DAVTA Neurons That Responded to
Lorcaserin
Genotype Total Depolarized Hyperpolarized Irresponsive
WT 45 26 (57.78)a 1 (2.22) 18 (40.00)a
WT 1 Blockers 18 14 (77.78)a 0 (0) 4 (22.22)a
DA-2C-KO 18 1 (5.56) 0 (0) 17 (94.44)
DA-2C-RE 24 16 (66.67)a 0 (0) 8 (33.33)a
Values are count or n (% of count in total cell). Depolarization was
deﬁned as .2 mV elevations in resting membrane potential within 3
min after lorcaserin application; hyperpolarization was deﬁned as .2
mV reductions in resting membrane potential within 3 min after
lorcaserin application; other neurons were deﬁned as irresponsive.
DA, dopamine; KO, knockout; RE, re-expression; VTA, ventral
tegmental area; WT, wild type.
ap , .01 vs. DA-2C-KO group in chi-square test.
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(ﬂuoxetine and d-Fen) and the selective 5-HT2CR agonist
(lorcaserin) effectively suppressed binge-like eating in WT
mice. These effects were attenuated in 2C-null mice lacking
5-HT2CRs globally or in DA-2C-KO mice that lack 5-HT2CRs
only in DA neurons. Furthermore, re-expression of 5-HT2CRs
only in DA neurons in DA-2C-RE mice restored antibinge
effects of these 5-HT medications close to the level observed
in WT mice. Thus, these results highlight the importance of
5-HT2CRs in DA neurons in the regulation of binge-like eating.
The functional relevance of this 5-HT→DA neural circuit was
further examined using both excitatory and inhibitory chemo-
genetic approaches. We demonstrated that activation of
DAVTA neurons inhibits binge-like eating, simulating effects of
5-HT drugs, whereas inhibition of DAVTA neurons blocks
antibinge effects of 5-HT drugs. Collectively, our results
indicate that 5-HT activates DAVTA neurons, which results in
inhibition of binge-like eating. It is worth mentioning that
binge-like eating is only affected by activities of DA neurons
in the VTA, but not by those in the SN. Consistently, it has
been reported that electric stimulation of the nucleus accum-
bens, a region receiving intensive dopaminergic inputs from
the VTA, potently inhibits binge-like eating in mice (24). On the
other hand, electric stimulation of the dorsal striatum, a region
receiving dopaminergic inputs from the SN, has been reported
to have no effect on binge-like eating (24).
Identiﬁcation of the action target for 5-HT to inhibit binge-
like eating in animals may facilitate development of more
selective and safer therapeutic interventions for binge eating in
humans. We revealed that the majority of antibinge beneﬁts
induced by ﬂuoxetine and d-Fen are mediated by the 5-
HT2CR. Providing a rationale for the clinical adoption of a 5-
HT2CR agonist for the treatment of binge eating, we report that
the Food and Drug Administration–approved drug lorcaserin
(used for weight management) effectively suppresses binge-
like eating in mice. Furthermore, we observed that these
effects are largely mediated by 5-HT2CRs in DA neurons.
Together, our results provide compelling preclinical evidence
for lorcaserin for the treatment of binge eating.
Both d-Fen (45,46) and lorcaserin (38) suppress hunger-
driven feeding through 5-HT2CR-mediated mechanisms. Thus,
an important question is whether effects of 5-HT2CRs in DA
neurons on binge-like eating are dependent on regulations on
hunger-driven feeding. To distinguish binge-like eating fromBiologicahunger-driven feeding behavior, we used a fast-induced
refeeding paradigm to directly examine effects of lorcaserin
on hunger-driven food intake. Lorcaserin suppressed fast-
induced refeeding in WT mice, but not in 2C-null mice. These
ﬁndings were consistent with the known effects of lorcaserin
(38) and the established roles of 5-HT2CRs in the regulation
of hunger-driven feeding (33,47). However, the lorcaserin-
induced anorexia in this fast-refeeding paradigm was not
affected by deletion of 5-HT2CRs in DA neurons, nor was it
rescued by restoration of 5-HT2CRs only in DA neurons. Such
ﬁndings indicate that 5-HT2CRs in DA neurons are not involved
in regulation of hunger-driven feeding behavior.
In summary, our data support a model in which 5-HT
stimulates DA neural activity through a 5-HT2CR-mediated
mechanism, and activation of this midbrain 5-HT→DA neural
circuit effectively inhibits binge-like eating behavior in mice.
We identiﬁed the 5-HT2CR population in DA neurons as one
potential target for antibinge therapies. Finally, we provided
preclinical evidence that the Food and Drug Administration–
approved 5-HT2CR agonist, lorcaserin, can be repurposed for
the treatment of binge eating.
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